File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)

TitlePhase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)
Authors
Issue Date2010
Citation
Journal of Thoracic Oncology, 2010, v. 5 n. 10, p. 1644-1648 How to Cite?
AbstractIntroduction: Treatment of small cell lung cancer (SCLC) is initially gratifying with most patients responding to platinum-based chemotherapy. Treatment of relapsed disease gives much lower response rates of short duration. We undertook this study of the protein deacetylase inhibitor Romidepsin in chemosensitive recurrent SCLC based on preclinical data that suggested this to be an active target. Methods: Patients had recurrent chemosensitive SCLC (relapse ≥90 days since completion of platinum-based chemotherapy). Treatment was administered as weekly infusions of Romidepsin at 13 mg/m2 for 3 of 4 weeks. We designed a two-stage phase II study targeting a response rate of 30% (<10% response would be uninteresting and ≥30% worthy of further study). Results: Sixteen patients (10 male, 6 female) were accrued to the first stage of this study. Most (11 patients, 69%) presented with extensive-stage SCLC, and all had received prior chemotherapy, with 11 having received prior radiation. Eastern Cooperative Oncology Group performance status was excellent with 0 in 6 patients (38%) and 1 in 10 patients. No objective responses were seen, and stable disease was the best response seen in 3 patients (19%). Toxicity was modest with 3 patients suffering grade 3 toxicity (lymphopenia, insomnia, nausea, vomiting, and hyponatremia) and one patient with grade 4 thrombocytopenia. Median progression-free survival was 1.8 months, and median overall survival was 6 months. Conclusion: Romidepsin given on a weekly schedule in patients with chemosensitive, recurrent SCLC was inactive and will not be pursued further in this setting. Copyright © 2010 by the International Association for the Study of Lung Cancer.
Persistent Identifierhttp://hdl.handle.net/10722/194291
ISSN
2015 Impact Factor: 5.04
2015 SCImago Journal Rankings: 2.597
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorOtterson, GA-
dc.contributor.authorHodgson, L-
dc.contributor.authorPang, H-
dc.contributor.authorVokes, EE-
dc.date.accessioned2014-01-30T03:32:24Z-
dc.date.available2014-01-30T03:32:24Z-
dc.date.issued2010-
dc.identifier.citationJournal of Thoracic Oncology, 2010, v. 5 n. 10, p. 1644-1648-
dc.identifier.issn1556-0864-
dc.identifier.urihttp://hdl.handle.net/10722/194291-
dc.description.abstractIntroduction: Treatment of small cell lung cancer (SCLC) is initially gratifying with most patients responding to platinum-based chemotherapy. Treatment of relapsed disease gives much lower response rates of short duration. We undertook this study of the protein deacetylase inhibitor Romidepsin in chemosensitive recurrent SCLC based on preclinical data that suggested this to be an active target. Methods: Patients had recurrent chemosensitive SCLC (relapse ≥90 days since completion of platinum-based chemotherapy). Treatment was administered as weekly infusions of Romidepsin at 13 mg/m2 for 3 of 4 weeks. We designed a two-stage phase II study targeting a response rate of 30% (<10% response would be uninteresting and ≥30% worthy of further study). Results: Sixteen patients (10 male, 6 female) were accrued to the first stage of this study. Most (11 patients, 69%) presented with extensive-stage SCLC, and all had received prior chemotherapy, with 11 having received prior radiation. Eastern Cooperative Oncology Group performance status was excellent with 0 in 6 patients (38%) and 1 in 10 patients. No objective responses were seen, and stable disease was the best response seen in 3 patients (19%). Toxicity was modest with 3 patients suffering grade 3 toxicity (lymphopenia, insomnia, nausea, vomiting, and hyponatremia) and one patient with grade 4 thrombocytopenia. Median progression-free survival was 1.8 months, and median overall survival was 6 months. Conclusion: Romidepsin given on a weekly schedule in patients with chemosensitive, recurrent SCLC was inactive and will not be pursued further in this setting. Copyright © 2010 by the International Association for the Study of Lung Cancer.-
dc.languageeng-
dc.relation.ispartofJournal of Thoracic Oncology-
dc.titlePhase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304)-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/JTO.0b013e3181ec1713-
dc.identifier.pmid20871263-
dc.identifier.scopuseid_2-s2.0-77958185126-
dc.identifier.volume5-
dc.identifier.issue10-
dc.identifier.spage1644-
dc.identifier.epage1648-
dc.identifier.isiWOS:000282122000023-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats